DR. SUCHARU PRAKASH MD NPI 1184667628

NPI Details

DR. Sucharu Prakash, MD is a medical oncology internal medicine in Paris, TX with 35 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Sucharu Prakash, MD NPI is 1184667628. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

3550 NE LOOP 286
PARIS, TX
ZIP 75460-004
Phone: (903) 785-0031
Fax: (903) 784-6755

The NPI 1184667628 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev (HCPCS:G6013)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Ct scan of chest with contrast (HCPCS:71260)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Ct scan of chest without contrast (HCPCS:71250)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Blood creatinine level (HCPCS:82565)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Drawing of blood for a medical problem (HCPCS:99195)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Ct scan of abdomen with contrast (HCPCS:74160)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Ct scan of head or brain before and after contrast (HCPCS:70470)

The enumeration date for this NPI number is 6/13/2006 and was last updated on 3/5/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.